(2r)-1-(Heptadecanoyloxy)-3-{[(R)-Hydroxy{[(1r,2r,3r,4r,5s,6r)-2,3,5,6-Tetrahydroxy-4-(Phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-Yl (5z,8z,11z,14z)-Icosa-5,8,11,14-Tetraenoate
(2r)-1-(Heptadecanoyloxy)-3-{[(R)-Hydroxy{[(1r,2r,3r,4r,5s,6r)-2,3,5,6-Tetrahydroxy-4-(Phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-Yl (5z,8z,11z,14z)-Icosa-5,8,11,14-Tetraenoate
| SMILES | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(=O)(O)OC1[C@H](O)[C@H](O)C(OP(=O)(O)O)[C@H](O)[C@H]1O |
| InChIKey | WSLBJQQQZZTFBA-XCXOWSJPSA-N |
Chemical Properties
| Hydrogen bond acceptors | None |
| Hydrogen bond donors | None |
| Rotatable bonds | None |
| Molecular weight (Da) |
No bioactivity data available.
(2r)-1-(Heptadecanoyloxy)-3-{[(R)-Hydroxy{[(1r,2r,3r,4r,5s,6r)-2,3,5,6-Tetrahydroxy-4-(Phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-Yl (5z,8z,11z,14z)-Icosa-5,8,11,14-Tetraenoate
Drug properties
| Molecular type | Small molecule |
| Physiological/Surrogate | Surrogate |
| Approved drug | No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV